Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?
11:38am, Friday, 31'st Oct 2025
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock
01:01pm, Thursday, 30'th Oct 2025
Arcutis Biotherapeutics (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Tori Spelling shares her and her family's journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded top
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
08:00am, Thursday, 30'th Oct 2025
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can
Arcutis' Q3 Earnings: Increased Foam Share, Better GTN, And Clear 2026 Guide Made Share Rally
10:54pm, Tuesday, 28'th Oct 2025
Arcutis Biotherapeutics delivered strong Q3 results, driven by Zoryve foam's rapid adoption and a shift toward more patent-protected revenue. ARQT achieved earlier-than-expected profitability, establi
Arcutis Biotherapeutics, Inc. (ARQT) Analyst/Investor Day Transcript
06:21pm, Tuesday, 28'th Oct 2025
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Analyst/Investor Day October 28, 2025 10:30 AM EDT Company Participants Brian Schoelkopf Todd Watanabe - President, CEO & Director Todd Edwards Latha Vaira
Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade)
03:26pm, Tuesday, 28'th Oct 2025
Arcutis Biotherapeutics, Inc. surges after Q3 earnings, driven by strong Zoryve sales and outperformance versus Wall Street expectations. ARQT reported $99.2M in Q3 revenue (up 122% YoY), achieved pro
Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today
12:00pm, Tuesday, 28'th Oct 2025
Management's medium-term sales target for its Zoryve franchise pleased investors. Its near-term sales estimate for 2026 also blasted past analyst estimates.
Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates
10:36am, Tuesday, 28'th Oct 2025
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
08:30am, Tuesday, 28'th Oct 2025
Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and
Arcutis to Present at Upcoming Investor Conferences
04:00pm, Monday, 27'th Oct 2025
WESTLAKE VILLAGE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
WESTLAKE VILLAGE, Calif. and LAS VEGAS, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:07am, Tuesday, 21'st Oct 2025
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
08:00am, Monday, 06'th Oct 2025
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 03'rd Oct 2025
WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
